Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 436 AL 450

Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease

Prins S, de Kam ML, Teunissen CE, Groeneveld GJ.

Alzheimers Res Ther. 2022 Aug 3;14(1):106. doi: 10.1186/s13195-022-01051-2.

Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer's disease

Vandendriessche C, Kapogiannis D, Vandenbroucke RE.

Adv Drug Deliv Rev. 2022 Nov;190:114486. doi: 10.1016/j.addr.2022.114486. Epub 2022 Aug 8.

Exploring Plausible Therapeutic Targets for Alzheimer's Disease using Multi-omics Approach, Machine Learning and Docking

Parvathy Dharshini SA, Sneha NP, Yesudhas D, Kulandaisamy A, Rangaswamy U, Shanmugam A, Taguchi YH, Gromiha MM.

Curr Top Med Chem. 2022;22(22):1868-1879. doi: 10.2174/1568026622666220902110115.

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

Jansen IE, van der Lee SJ, Gomez-Fonseca D, de Rojas I, Dalmasso MC, Grenier-Boley B, Zettergren A, Mishra A, Ali M, Andrade V, Bellenguez C, Kleineidam L, Küçükali F, Sung YJ, Tesí N, Vromen EM, Wightman DP, Alcolea D, Alegret M, Alvarez I, Amouyel P, Athanasiu L, Bahrami S, Bailly H, Belbin O, Bergh S, Bertram L, Biessels GJ, Blennow K, Blesa R, Boada M, Boland A, Buerger K, Carracedo Á, Cervera-Carles L, Chene G, Claassen JAHR, Debette S, Deleuze JF, de Deyn PP, Diehl-Schmid J, Djurovic S, Dols-Icardo O, Dufouil C, Duron E, Düzel E; EADB consortium; Fladby T, Fortea J, Frölich L, García-González P, Garcia-Martinez M, Giegling I, Goldhardt O, Gobom J, Grimmer T, Haapasalo A, Hampel H, Hanon O, Hausner L, Heilmann-Heimbach S, Helisalmi S, Heneka MT, Hernández I, Herukka SK, Holstege H, Jarholm J, Kern S, Knapskog AB, Koivisto AM, Kornhuber J, Kuulasmaa T, Lage C, Laske C, Leinonen V, Lewczuk P, Lleó A, de Munain AL, Lopez-Garcia S, Maier W, Marquié M, Mol MO, Montrreal L, Moreno F, Moreno-Grau S, Nicolas G, Nöthen MM, Orellana A, Pålhaugen L, Papma JM, Pasquier F, Perneczky R, Peters O, Pijnenburg YAL, Popp J, Posthuma D, Pozueta A, Priller J, Puerta R, Quintela I, et al.

Acta Neuropathol. 2022 Nov;144(5):821-842. doi: 10.1007/s00401-022-02454-z. Epub 2022 Sep 6.

Demand Coupling Drives Neurodegeneration: A Model of Age-Related Cognitive Decline and Dementia

Turknett J, Wood TR.

Cells. 2022 Sep 7;11(18):2789. doi: 10.3390/cells11182789.

Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil

Alvarez XA, Winston CN, Barlow JW, Sarsoza FM, Alvarez I, Aleixandre M, Linares C, García-Fantini M, Kastberger B, Winter S, Rissman RA.

J Alzheimers Dis. 2022;90(2):705-717. doi: 10.3233/JAD-220575.

Somatic Mutations and Alzheimer's Disease

Downey J, Lam JCK, Li VOK, Gozes I.

J Alzheimers Dis. 2022;90(2):475-493. doi: 10.3233/JAD-220643.

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

Villain N, Planche V, Levy R.

Rev Neurol (Paris). 2022 Dec;178(10):1011-1030. doi: 10.1016/j.neurol.2022.06.012. Epub 2022 Sep 29.

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA.

JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392.

Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential

Olichney J, Xia J, Church KJ, Moebius HJ.

Neural Plast. 2022 Nov 8;2022:2104880. doi: 10.1155/2022/2104880. eCollection 2022.

Dementia Prevention in Clinical Practice

Niotis K, Akiyoshi K, Carlton C, Isaacson R.

Semin Neurol. 2022 Oct;42(5):525-548. doi: 10.1055/s-0042-1759580. Epub 2022 Nov 28.

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ.

Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias